CDKN2A and pancreatic neoplasm: Among 178 CDKN2A mutation carriers, PDAC was found in 7.3% (N = 13), 0.9% in the familial pancreatic cancer group (N = 2; 1 advanced PDAC, 1 grade 2 neuroendocrine tumour [NET]) and 1 PDAC was diagnosed among BRCA2 carriers.